TY - JOUR
T1 - Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events With Systolic Blood Pressure <120 mm Hg Versus 135-139 mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup
AU - Plante, Timothy B.
AU - Juraschek, Stephen P.
AU - Miller, Edgar R.
AU - Appel, Lawrence J.
AU - Cushman, Mary
AU - Littenberg, Benjamin
N1 - Funding Information:
We would like to thank the SPRINT investigators, SPRINT participants, staff at the NIH BioLINCC, and the NHLBI, NIDDK, NINDS, and NIA at the NIH. Dr. Timothy B. Plante MD, MHS was supported by an Institutional National Research Service Award from HRSA T32 HP10025B0 (Baltimore, MD) and the NIH-NHLBI 2T32HL007180-41A1 (Baltimore, MD) . Dr. Juraschek was sponsored by a NIH-NIDDK Renal Disease Epidemiology Training Grant T32DK007732-20 (Baltimore, MD) and is sponsored by an NIH-NHLBI career development award 7K23HL135273-02 (Boston, MA) .
Funding Information:
We would like to thank the SPRINT investigators, SPRINT participants, staff at the NIH BioLINCC, and the NHLBI, NIDDK, NINDS, and NIA at the NIH. Dr. Timothy B. Plante MD, MHS was supported by an Institutional National Research ServiceAward from HRSA T32 HP10025B0 (Baltimore, MD) and the NIH-NHLBI 2T32HL007180-41A1 (Baltimore, MD). Dr. Juraschek was sponsored by a NIH-NIDDK Renal Disease Epidemiology Training Grant T32DK007732-20 (Baltimore, MD) and is sponsored by an NIH-NHLBIcareer development award 7K23HL135273-02 (Boston, MA).
Publisher Copyright:
© 2018
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Whether the benefit of intensive blood pressure (BP) control reduces atherosclerotic cardiovascular disease (ASCVD) risk without increasing risks of serious adverse events (SAEs) is unknown. We sought to assess differences in incident ASCVD and SAE with intensive BP control across the spectrum of 10-year ASCVD risk in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT randomized 9,361 participants who were ≥50 years old and ≥1 CVD risk factor to standard or intensive BP control (<120 or 130 to 139 mm Hg). We excluded adults with clinical ASCVD or age ≥80. We included 6,875 participants. We compared hazard ratios (HR) and risk differences (RD) of incident ASCVD events or SAEs in all and across quartiles of baseline risk. Median predicted ASCVD risk was 15.9%. Intensive BP control significantly reduced ASCVD events (HR 0.75, 95% confidence interval 0.58, 0.97, p = 0.03; RD ˗0.94; ˗1.8, ˗0.1; p = 0.03). There was no difference in effect across quartiles of ASCVD risk. There was a non-significant increase in SAE with intensive BP control (HR 1.08, 1.00, 1.17 p = 0.06; RD 2.1, ˗0.1, 4.4, p = 0.03), and no difference in this effect across quartiles of risk. In SPRINT participants without baseline clinical ASCVD, the benefit of intensive BP control for primary prevention of ASCVD may extend to lower risk participants without an increase in SAE. In conclusion, lower risk adults with stage 1 hypertension meeting SPRINT eligibility may benefit from initiation of antihypertensives.
AB - Whether the benefit of intensive blood pressure (BP) control reduces atherosclerotic cardiovascular disease (ASCVD) risk without increasing risks of serious adverse events (SAEs) is unknown. We sought to assess differences in incident ASCVD and SAE with intensive BP control across the spectrum of 10-year ASCVD risk in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT randomized 9,361 participants who were ≥50 years old and ≥1 CVD risk factor to standard or intensive BP control (<120 or 130 to 139 mm Hg). We excluded adults with clinical ASCVD or age ≥80. We included 6,875 participants. We compared hazard ratios (HR) and risk differences (RD) of incident ASCVD events or SAEs in all and across quartiles of baseline risk. Median predicted ASCVD risk was 15.9%. Intensive BP control significantly reduced ASCVD events (HR 0.75, 95% confidence interval 0.58, 0.97, p = 0.03; RD ˗0.94; ˗1.8, ˗0.1; p = 0.03). There was no difference in effect across quartiles of ASCVD risk. There was a non-significant increase in SAE with intensive BP control (HR 1.08, 1.00, 1.17 p = 0.06; RD 2.1, ˗0.1, 4.4, p = 0.03), and no difference in this effect across quartiles of risk. In SPRINT participants without baseline clinical ASCVD, the benefit of intensive BP control for primary prevention of ASCVD may extend to lower risk participants without an increase in SAE. In conclusion, lower risk adults with stage 1 hypertension meeting SPRINT eligibility may benefit from initiation of antihypertensives.
UR - http://www.scopus.com/inward/record.url?scp=85051377280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051377280&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2018.06.041
DO - 10.1016/j.amjcard.2018.06.041
M3 - Article
C2 - 30115425
AN - SCOPUS:85051377280
SN - 0002-9149
VL - 122
SP - 1185
EP - 1190
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 7
ER -